610 related articles for article (PubMed ID: 30676622)
21. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
22. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
[TBL] [Abstract][Full Text] [Related]
24. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
25. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
26. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E; Lynam S; Attwood KM; Wang C; Chilakapati S; Gomez EC; Liu S; Akers S; Lele S; Frederick PJ; Odunsi K
JAMA Oncol; 2021 Jan; 7(1):78-85. PubMed ID: 33211063
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
[TBL] [Abstract][Full Text] [Related]
29. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
Le Tourneau C; Hoimes C; Zarwan C; Wong DJ; Bauer S; Claus R; Wermke M; Hariharan S; von Heydebreck A; Kasturi V; Chand V; Gulley JL
J Immunother Cancer; 2018 Oct; 6(1):111. PubMed ID: 30348224
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
31. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
34. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Konstantinopoulos PA; Gockley AA; Xiong N; Krasner C; Horowitz N; Campos S; Wright AA; Liu JF; Shea M; Yeku O; Castro C; Polak M; Lee EK; Sawyer H; Bowes B; Moroney J; Cheng SC; Tayob N; Bouberhan S; Spriggs D; Penson RT; Fleming GF; Nucci MR; Matulonis UA
JAMA Oncol; 2022 Sep; 8(9):1317-1322. PubMed ID: 35900726
[TBL] [Abstract][Full Text] [Related]
38. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
40. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Joly F; Hajri T; Maucort-Boulch D; Bin S; Rousset P; Devouassoux-Shisheboran M; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Langlois-Jacques C; Mercier C; Villeneuve L; Freyer G; Golfier F
J Clin Oncol; 2020 Sep; 38(27):3129-3137. PubMed ID: 32716740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
